We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Aclaris (ACRS) Could Be Positioned for a Surge
Read MoreHide Full Article
Aclaris Therapeutics, Inc. (ACRS - Free Report) , a dermatologist-led specialty pharmaceutical company, could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ACRS’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Aclaris could be a solid choice for investors.
Current Quarter Estimates for ACRS
In the past 30 days, 2 estimates have gone higher for Aclaris while no estimates have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 75 cents a share 30 days ago, to a loss of 61 cents today, a move of 18.7%.
Current Year Estimates for ACRS
Meanwhile, Aclaris’s current year figures are also looking quite promising, with 2 estimates moving higher in the past month, compared to no lower estimates. The consensus estimate trend has also seen a boost for this time frame, narrowing from $2.70 per share 30 days ago to $2.38 per share today, an increase of 11.9%.
The stock has also started to move higher lately, adding 41.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Aclaris (ACRS) Could Be Positioned for a Surge
Aclaris Therapeutics, Inc. (ACRS - Free Report) , a dermatologist-led specialty pharmaceutical company, could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ACRS’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Aclaris could be a solid choice for investors.
Current Quarter Estimates for ACRS
In the past 30 days, 2 estimates have gone higher for Aclaris while no estimates have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 75 cents a share 30 days ago, to a loss of 61 cents today, a move of 18.7%.
Current Year Estimates for ACRS
Meanwhile, Aclaris’s current year figures are also looking quite promising, with 2 estimates moving higher in the past month, compared to no lower estimates. The consensus estimate trend has also seen a boost for this time frame, narrowing from $2.70 per share 30 days ago to $2.38 per share today, an increase of 11.9%.
ACLARIS THERAPT Price and Consensus
ACLARIS THERAPT Price and Consensus | ACLARIS THERAPT Quote
Bottom Line
The stock has also started to move higher lately, adding 41.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>